Peacock E
ANNA J. 1992 Dec;19(6):575-7.
The introduction of synthetically produced calcitriol in the early 1970s was an important contribution to the prevention and treatment of renal bone disease. However, despite the efficacy and the availability of oral calcitriol many dialysis patients continued to develop secondary hyperparathyroidism (Norris, 1991). Effective treatment was often impossible in patients with osteitis fibrosa because even low oral doses of calcitriol could cause hypercalcemia (Andress, Norris, Coburn, Slatopolsky, & Sherrad, 1989). From 1981 to the present, numerous studies have been conducted that have demonstrated intravenous calcitriol as being more effective and having several advantages over the oral route of administration, particularly in patients with poor compliance and those with a tendency to develop hypercalcemia.
20世纪70年代初合成生产的骨化三醇的引入，对肾性骨病的预防和治疗做出了重要贡献。然而，尽管口服骨化三醇有效且可得，但许多透析患者仍继续发生继发性甲状旁腺功能亢进（诺里斯，1991年）。纤维性骨炎患者往往无法进行有效治疗，因为即使口服低剂量的骨化三醇也可能导致高钙血症（安德雷斯、诺里斯、科伯恩、斯拉托波尔斯基和谢拉德，1989年）。从1981年至今，已经进行了大量研究，这些研究表明静脉注射骨化三醇比口服给药更有效，并且有几个优点，特别是对于依从性差的患者和有发生高钙血症倾向的患者。
